Enliven Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Public

  • Employees
  • 65

Employees

  • Stock Symbol
  • ELVN

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $46.53
  • (As of Friday Closing)

Enliven Therapeutics General Information

Description

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 205 Park Road
  • Burlingame, CA 94010
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 205 Park Road
  • Burlingame, CA 94010
  • United States
+1 (650)

Enliven Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enliven Therapeutics Stock Performance

As of 20-Nov-2026, Enliven Therapeutics’s stock price is $46.53. Its current market cap is $3.42B with 73.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$46.53 $46.41 $14.79 - $62.32 $3.42B 73.6M 1.35M -$1.69

Enliven Therapeutics Financials Summary

As of 30-Sep-2026, Enliven Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,464,174 436,771 807,582 307,228
Revenue 0 0 0 0
EBITDA (135,301) (119,444) (103,366) (83,254)
Net Income (113,482) (103,694) (89,024) (71,584)
Total Assets 897,225 476,168 325,760 271,867
Total Debt 1,315 399 0 335
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Enliven Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Enliven Therapeutics‘s full profile, request access.

Request a free trial

Enliven Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Enliven Therapeutics‘s full profile, request access.

Request a free trial

Enliven Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small
Drug Discovery
Burlingame, CA
65 As of 2026

Brisbane, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Enliven Therapeutics Competitors (3)

One of Enliven Therapeutics’s 3 competitors is Tempest Therapeutics, a Formerly VC-backed company based in Brisbane, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tempest Therapeutics Formerly VC-backed Brisbane, CA
Flare Therapeutics Venture Capital-Backed Cambridge, MA
Centrose Venture Capital-Backed Madison, WI
You’re viewing 3 of 3 competitors. Get the full list »

Enliven Therapeutics Patents

Enliven Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023154124-A1 Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 Inactive 09-Feb-2022
WO-2023077259-A1 Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 Inactive 02-Nov-2021
WO-2023081637-A1 Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 Inactive 02-Nov-2021
WO-2023014748-A1 Nitrated fatty acids for the treatment of sickle cell disorders Inactive 03-Aug-2021
WO-2022236319-A1 Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases Inactive 07-May-2021 C07D471/04
To view Enliven Therapeutics’s complete patent history, request access »

Enliven Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enliven Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Enliven Therapeutics‘s full profile, request access.

Request a free trial

Enliven Therapeutics Acquisitions (1)

Enliven Therapeutics’s most recent deal was a Merger/Acquisition with Imara for . The deal was made on 23-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Imara 23-Feb-2023 Merger/Acquisition Drug Discovery
To view Enliven Therapeutics’s complete acquisitions history, request access »

Enliven Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.76 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Enliven Therapeutics’s complete esg history, request access »

Enliven Therapeutics FAQs

  • When was Enliven Therapeutics founded?

    Enliven Therapeutics was founded in 2019.

  • Where is Enliven Therapeutics headquartered?

    Enliven Therapeutics is headquartered in Burlingame, CA.

  • What is the size of Enliven Therapeutics?

    Enliven Therapeutics has 65 total employees.

  • What industry is Enliven Therapeutics in?

    Enliven Therapeutics’s primary industry is Drug Discovery.

  • Is Enliven Therapeutics a private or public company?

    Enliven Therapeutics is a Public company.

  • What is Enliven Therapeutics’s stock symbol?

    The ticker symbol for Enliven Therapeutics is ELVN.

  • What is the current stock price of Enliven Therapeutics?

    As of 20-Nov-2026 the stock price of Enliven Therapeutics is $46.53.

  • What is the current market cap of Enliven Therapeutics?

    The current market capitalization of Enliven Therapeutics is $3.42B.

  • Who are Enliven Therapeutics’s competitors?

    Tempest Therapeutics, Flare Therapeutics, and Centrose are competitors of Enliven Therapeutics.

  • What is Enliven Therapeutics’s annual earnings per share (EPS)?

    Enliven Therapeutics’s EPS for 12 months was -$1.69.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process